GNFT vs. MRK
GNFT (Genfit) and MRK (Merck & Co., Inc.) are both stocks. Both are in the Healthcare sector — GNFT in Biotechnology, MRK in Drug Manufacturers - General. Over the past 5 years, GNFT returned 3.52%/yr vs 13.69%/yr for MRK. At a 0.07 correlation, their price movements are largely independent.
Performance
GNFT vs. MRK - Performance Comparison
Loading charts...
Returns By Period
GNFT
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- 0.00%
- 6M
- 0.00%
- 1Y
- 8.50%
- 3Y*
- 4.91%
- 5Y*
- 3.52%
- 10Y*
- —
MRK
- 1D
- 4.85%
- 1M
- 6.28%
- YTD
- 15.10%
- 6M
- 21.11%
- 1Y
- 59.23%
- 3Y*
- 5.24%
- 5Y*
- 13.69%
- 10Y*
- 11.61%
GNFT vs. MRK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
GNFT Genfit | 0.00% | 30.55% | -3.51% | -12.28% | -12.22% | 4.17% | -75.88% | -10.24% |
MRK Merck & Co., Inc. | 15.10% | 9.79% | -6.26% | 1.01% | 49.42% | 1.75% | -7.20% | 12.77% |
Correlation
The correlation between GNFT and MRK is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.04 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.04 |
Correlation (All Time) Calculated using the full available price history since Mar 28, 2019 | 0.07 |
Fundamentals
GNFT:
$241.46M
MRK:
$297.28B
GNFT:
-$0.33
MRK:
$3.58
GNFT:
2.07
MRK:
4.57
GNFT:
4.60
MRK:
6.48
GNFT:
$116.80M
MRK:
$65.59B
GNFT:
$122.47M
MRK:
$49.79B
GNFT:
-$1.40M
MRK:
$22.69B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GNFT vs. MRK — Risk / Return Rank
GNFT
MRK
GNFT vs. MRK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Genfit (GNFT) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GNFT | MRK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.94 | ||
| Sortino ratioReturn per unit of downside risk | -2.46 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.38 | -0.27 |
| Calmar ratioReturn relative to maximum drawdown | 0.52 | 5.24 | -4.72 |
| Martin ratioReturn relative to average drawdown | 1.26 | 13.14 | -11.88 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GNFT | MRK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.24 | 2.18 | -1.94 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.06 | 0.58 | -0.52 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.51 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.29 | 0.48 | -0.77 |
Drawdowns
GNFT vs. MRK - Drawdown Comparison
The maximum GNFT drawdown since its inception was -89.42%, which is greater than MRK's maximum drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for GNFT and MRK.
Loading charts...
Drawdown Indicators
| GNFT | MRK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.42% | -68.61% | -20.81% |
Max Drawdown (1Y)Largest decline over 1 year | -21.50% | -11.37% | -10.13% |
Max Drawdown (3Y)Largest decline over 3 years | -57.11% | -43.44% | -13.67% |
Max Drawdown (5Y)Largest decline over 5 years | -57.11% | -43.44% | -13.67% |
Max Drawdown (10Y)Largest decline over 10 years | — | -43.44% | — |
Current DrawdownCurrent decline from peak | -81.09% | -4.06% | -77.03% |
Average DrawdownAverage peak-to-trough decline | -74.63% | -18.84% | -55.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.93% | 4.52% | +5.41% |
Volatility
GNFT vs. MRK - Volatility Comparison
The current volatility for Genfit (GNFT) is 0.00%, while Merck & Co., Inc. (MRK) has a volatility of 9.44%. This indicates that GNFT experiences smaller price fluctuations and is considered to be less risky than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GNFT | MRK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.00% | 9.44% | -9.44% |
Volatility (6M)Calculated over the trailing 6-month period | 26.84% | 18.19% | +8.65% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.31% | 27.31% | +19.00% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 61.57% | 23.72% | +37.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 68.09% | 22.96% | +45.13% |
Dividends
GNFT vs. MRK - Dividend Comparison
GNFT has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 2.76%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GNFT Genfit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MRK Merck & Co., Inc. | 2.76% | 3.12% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% |
Financials
GNFT vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Genfit and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GNFT vs. MRK - Profitability Comparison
GNFT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Genfit reported a gross profit of 35.54M and revenue of 35.54M. Therefore, the gross margin over that period was 100.0%.
MRK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported a gross profit of 13.34B and revenue of 16.29B. Therefore, the gross margin over that period was 81.9%.
GNFT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Genfit reported an operating income of 76.00K and revenue of 35.54M, resulting in an operating margin of 0.2%.
MRK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported an operating income of -1.88B and revenue of 16.29B, resulting in an operating margin of -11.6%.
GNFT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Genfit reported a net income of -9.96M and revenue of 35.54M, resulting in a net margin of -28.0%.
MRK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported a net income of -4.24B and revenue of 16.29B, resulting in a net margin of -26.0%.
Frequently Asked Questions
GNFT and MRK have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MRK has higher volatility (9.44%) compared to GNFT (0.00%). In terms of maximum drawdown, GNFT dropped -89.42% vs MRK's -68.61%.
MRK currently has the higher Sharpe Ratio (2.18 vs 0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GNFT and MRK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer